Xihua Sun, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 8 carriers
- Office
- 1
Offices
1 location
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
28 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sun’s office at (408) 557-0550 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A55886 · Current
Licensed to practise in California · since 1996 · expires 2027-12-31 · Jiamusi Medical College Aka Chiamuszu Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$131,680
Medicare paid this office $131,680 for 196 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 27 | $57,229 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $20,483 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $15,218 | $141 |
| Critical care, first 30-74 minutes | 23 | $12,003 | $185 |
| Return visit (30+ min) | 50 | $11,866 | $100 |
See all 8 services
| Botox | 27 | $57,229 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $20,483 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $15,218 | $141 |
| Critical care, first 30-74 minutes | 23 | $12,003 | $185 |
| Return visit (30+ min) | 50 | $11,866 | $100 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 25 | $9,125 | $129 |
| New patient visit (60+ min) | 19 | $3,492 | $184 |
| Measurement of brain wave activity (eeg), awake and asleep | 27 | $1,265 | $45 |
Who their Medicare patients are
196 Original Medicare patients in 2024. Average age 76 · Under 65 10% · 85 and older 20% · Women 56% · Also on Medicaid 64% · Health risk score 2.07. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 53% · Diabetes 52% · Coronary heart disease 35% · Chronic kidney disease 34% · Dementia 34% · Depression 29% · Heart failure 27% · Atrial fibrillation 24% · COPD 17% · Cancer 10%.
The office billed $273,298, Medicare allowed $172,154 and paid $131,680; for 12,160 services of 10 kinds; $57,229 of it was for drugs given in the office and $74,451 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 196 | 12,160 | 76 | 2.07 | $273,298 | $131,680 |
| 2023 | 226 | 14,699 | 76 | 1.84 | $339,326 | $162,303 |
| 2022 | 246 | 18,109 | 76 | 2.04 | $390,956 | $193,178 |
| 2021 | 205 | 18,208 | 76 | 1.86 | $416,575 | $209,641 |
| 2020 | 179 | 11,916 | 75 | 2.41 | $287,440 | $151,962 |
| 2019 | 253 | 20,032 | 76 | 2.23 | $471,018 | $208,495 |
| 2018 | 229 | 18,880 | 78 | 2.01 | $380,501 | $184,201 |
| 2017 | 224 | 14,189 | 77 | 2.34 | $312,211 | $155,087 |
| 2016 | 231 | 15,701 | 77 | 1.98 | $344,486 | $168,427 |
| 2015 | 252 | 19,302 | 77 | 2.11 | $378,035 | $173,940 |
| 2014 | 379 | 20,879 | 77 | 2.00 | $468,087 | $226,306 |
| 2013 | 467 | 19,088 | 76 | 1.82 | $549,737 | $298,107 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Botox | 27 | $68,878 | None |
| Critical care, first 30-74 minutes | 33 | $22,742 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $20,409 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $17,047 | $152 |
| Return visit (30+ min) | 68 | $15,043 | $99 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 26 | $9,698 | $123 |
| New patient visit (60+ min) | 24 | $4,068 | $169 |
| Measurement of brain wave activity (eeg), awake and asleep | 31 | $1,864 | $52 |
2022: 8 services
| Botox | 32 | $83,812 | None |
| Critical care, first 30-74 minutes | 38 | $31,540 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $22,300 | $90 |
| Return visit (30+ min) | 71 | $18,186 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $12,749 | $175 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 30 | $9,733 | $130 |
| New patient visit (60+ min) | 53 | $9,725 | $183 |
| Measurement of brain wave activity (eeg), awake and asleep | 37 | $2,080 | $53 |
2021: 9 services
| Botox | 26 | $83,545 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $40,655 | $92 |
| Critical care, first 30-74 minutes | 33 | $38,854 | $197 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $13,939 | $174 |
| Return visit (30+ min) | 50 | $11,295 | $111 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 26 | $10,405 | $133 |
| Long return visit (40+ min) | 23 | $3,842 | $124 |
| New patient visit (60+ min) | 22 | $3,595 | $163 |
| Measurement of brain wave activity (eeg), awake and asleep | 33 | $2,015 | $54 |
2020: 9 services
| Botox | 19 | $52,016 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 111 | $37,409 | $92 |
| Critical care, first 30-74 minutes | 38 | $25,020 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $16,678 | $179 |
| Return visit (30+ min) | 35 | $6,825 | $95 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 17 | $4,809 | $127 |
| Long return visit (40+ min) | 17 | $3,398 | $136 |
| New patient visit (60+ min) | 14 | $2,650 | $189 |
| Measurement of brain wave activity (eeg), awake and asleep | 26 | $1,591 | $55 |
2019: 9 services
| Botox | 29 | $91,472 | None |
| Critical care, first 30-74 minutes | 47 | $35,582 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $25,067 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $19,789 | $164 |
| Return visit (30+ min) | 63 | $10,583 | $86 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 21 | $7,567 | $111 |
| Long return visit (40+ min) | 41 | $7,434 | $122 |
| New patient visit (60+ min) | 30 | $4,805 | $160 |
| Measurement of brain wave activity (eeg), awake and asleep | 37 | $2,299 | $50 |
2018: 8 services
| Botox | 30 | $86,765 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $22,111 | $90 |
| Critical care, first 30-74 minutes | 29 | $19,770 | $190 |
| Return visit (30+ min) | 96 | $19,023 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $18,699 | $176 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 25 | $7,359 | $107 |
| New patient visit (60+ min) | 30 | $5,258 | $175 |
| Long return visit (40+ min) | 17 | $2,646 | $126 |
2017: 7 services
| Botox | 25 | $62,649 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $24,075 | $90 |
| Critical care, first 30-74 minutes | 33 | $22,274 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $17,057 | $176 |
| Return visit (30+ min) | 73 | $16,395 | $85 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 22 | $5,716 | $108 |
| New patient visit (60+ min) | 17 | $2,563 | $151 |
2016: 10 services
| Botox | 24 | $67,300 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 90 | $24,798 | $90 |
| Critical care, first 30-74 minutes | 28 | $23,779 | $192 |
| Return visit (30+ min) | 92 | $19,329 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 88 | $15,430 | $173 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 21 | $5,720 | $117 |
| New patient visit (60+ min) | 25 | $4,362 | $174 |
| Long return visit (40+ min) | 19 | $2,523 | $126 |
| Measurement of brain wave activity (eeg), awake and asleep | 27 | $1,237 | $41 |
| Short return visit (20+ min) | 11 | $740 | $67 |
2015: 10 services
| Botox | 33 | $81,750 | None |
| Critical care, first 30-74 minutes | 35 | $21,510 | $194 |
| Return visit (30+ min) | 95 | $17,490 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $17,047 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $16,248 | $175 |
| New patient visit (60+ min) | 26 | $4,840 | $186 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 14 | $4,346 | $106 |
| Face injection for nerve paralysis | 11 | $4,173 | $107 |
| Long return visit (40+ min) | 18 | $2,163 | $120 |
| Measurement of brain wave activity (eeg), awake and asleep | 40 | $2,082 | $51 |
2014: 11 services
| Botox | 36 | $84,794 | None |
| Critical care, first 30-74 minutes | 52 | $37,335 | $195 |
| Return visit (30+ min) | 157 | $28,492 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $24,767 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 124 | $21,985 | $174 |
| New patient visit (60+ min) | 39 | $6,900 | $177 |
| Face injection for nerve paralysis | 18 | $5,549 | $118 |
| Short return visit (20+ min) | 45 | $3,816 | $67 |
| Measurement of brain wave activity (eeg), awake and asleep | 69 | $3,655 | $51 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $3,526 | $126 |
| Long return visit (40+ min) | 18 | $2,077 | $99 |
2013: 11 services
| Botox | 35 | $73,790 | None |
| Critical care, first 30-74 minutes | 84 | $62,062 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 191 | $51,457 | $90 |
| Return visit (30+ min) | 181 | $43,300 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 163 | $28,233 | $172 |
| New patient visit (60+ min) | 51 | $9,027 | $177 |
| Face injection for nerve paralysis | 24 | $8,598 | $116 |
| Long return visit (40+ min) | 45 | $8,083 | $122 |
| Measurement of brain wave activity (eeg), awake and asleep | 99 | $5,107 | $50 |
| Injection of chemical for destruction of arms legs and/or torso muscles | 11 | $3,888 | $185 |
| Short return visit (20+ min) | 21 | $1,809 | $62 |
Medicaid work
$1,543 in 2024
Medicaid paid $1,543 for 66 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 53 | $1,140 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $403 |
| 2024 | 66 | 2 | 13 | $1,543 |
| 2023 | 66 | 2 | 14 | $1,063 |
| 2022 | 30 | 1 | 14 | $113 |
| 2021 | 106 | 2 | 14 | $369 |
| 2018 | 12 | 1 | 12 | $314 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 52 | $875 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $188 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $113 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 92 | $209 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $160 |
2018
| 1ST HOSP IP/OBS HIGH 75 | 12 | $314 |
Drugs they prescribed that Part D paid
$288,368
Pharmacies billed $288,368 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 637) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
571 generic and fewer than 11 brand-name prescriptions · $288,368 in drug cost · 26 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rebif Rebidose | 12 | $120,195 | $10,016 |
| Copaxone | 12 | $82,975 | $6,915 |
| Nuedexta | 13 | $19,518 | $1,501 |
| Fycompa | 13 | $15,244 | $1,173 |
| Zolmitriptan Odt | 12 | $10,598 | $883 |
See all 17 drugs
| Rebif Rebidose | 12 | $120,195 | $10,016 |
| Copaxone | 12 | $82,975 | $6,915 |
| Nuedexta | 13 | $19,518 | $1,501 |
| Fycompa | 13 | $15,244 | $1,173 |
| Zolmitriptan Odt | 12 | $10,598 | $883 |
| Lamotrigine Odt | 13 | $10,124 | $779 |
| Levetiracetam | 69 | $2,473 | $36 |
| Gabapentin | 68 | $2,243 | $33 |
| Carbidopa-Levodopa | 72 | $2,010 | $28 |
| Lacosamide | 27 | $1,761 | $65 |
| Baclofen | 30 | $1,735 | $58 |
| Donepezil | 99 | $1,347 | $14 |
| Quetiapine | 30 | $855 | $29 |
| Memantine | 32 | $617 | $19 |
| Topiramate | 16 | $300 | $19 |
| Clonazepam | 16 | $148 | $9 |
| Escitalopram | 13 | $96 | $7 |
Year by year
| 2024 | 637 | 133 | 0% (0) | None | $288,368 |
| 2023 | 675 | 141 | 0% (0) | None | $514,438 |
| 2022 | 586 | 153 | 0% (0) | 14% | $438,242 |
| 2021 | 630 | 138 | 0% (0) | 13% | $467,483 |
| 2020 | 618 | 124 | 0% (0) | 11% | $460,756 |
| 2019 | 641 | 140 | 0% (0) | 11% | $435,712 |
| 2018 | 572 | 125 | None | 17% | $503,327 |
| 2017 | 641 | 112 | None | 21% | $400,663 |
| 2016 | 752 | 129 | 0% (0) | 26% | $441,755 |
| 2015 | 805 | 148 | 0% (0) | 31% | $469,073 |
| 2014 | 1,057 | 180 | None | 38% | $470,694 |
| 2013 | 1,108 | 198 | None | 34% | $296,736 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Rebif | 13 | $139,596 | $10,738 |
| Copaxone | 12 | $95,805 | $7,984 |
| Zolmitriptan Odt | 13 | $15,897 | $1,223 |
| Fycompa | 19 | $14,539 | $765 |
| Lacosamide | 24 | $4,813 | $201 |
| Carbidopa-Levodopa | 97 | $4,229 | $44 |
| Levetiracetam | 58 | $2,987 | $51 |
| Donepezil | 115 | $2,827 | $25 |
| Gabapentin | 64 | $1,809 | $28 |
| Quetiapine | 21 | $974 | $46 |
| Memantine | 23 | $932 | $41 |
| Baclofen | 17 | $924 | $54 |
| Topiramate | 16 | $786 | $49 |
| Clonazepam | 21 | $310 | $15 |
| Clopidogrel | 12 | $273 | $23 |
2022: 15 drugs
| Rebif Rebidose | 13 | $129,912 | $9,993 |
| Rebif | 12 | $117,378 | $9,781 |
| Copaxone | 12 | $92,197 | $7,683 |
| Botox | 24 | $32,005 | $1,334 |
| Zolmitriptan Odt | 12 | $17,658 | $1,472 |
| Carbidopa-Levodopa | 86 | $3,593 | $42 |
| Levetiracetam | 32 | $2,153 | $67 |
| Gabapentin | 71 | $2,149 | $30 |
| Baclofen | 20 | $1,647 | $82 |
| Donepezil | 94 | $1,609 | $17 |
| Quetiapine | 17 | $1,220 | $72 |
| Clopidogrel | 19 | $482 | $25 |
| Clonazepam | 21 | $362 | $17 |
| Escitalopram | 12 | $260 | $22 |
| Pantoprazole | 15 | $160 | $11 |
2021: 17 drugs
| Rebif | 12 | $116,357 | $9,696 |
| Rebif Rebidose | 12 | $112,454 | $9,371 |
| Copaxone | 12 | $90,661 | $7,555 |
| Zomig Zmt | 11 | $33,515 | $3,047 |
| Memantine Hcl Er | 12 | $4,418 | $368 |
| Carbidopa-Levodopa | 91 | $4,252 | $47 |
| Levetiracetam | 42 | $2,339 | $56 |
| Baclofen | 38 | $2,280 | $60 |
| Gabapentin | 61 | $2,094 | $34 |
| Donepezil | 79 | $1,006 | $13 |
| Propranolol | 15 | $581 | $39 |
| Escitalopram | 20 | $559 | $28 |
| Clopidogrel | 22 | $428 | $19 |
| Clonazepam | 16 | $315 | $20 |
| Pantoprazole | 14 | $183 | $13 |
| Prednisone | 15 | $175 | $12 |
| Verapamil | 17 | $111 | $7 |
2020: 20 drugs
| Rebif | 13 | $117,613 | $9,047 |
| Rebif Rebidose | 13 | $103,651 | $7,973 |
| Copaxone | 12 | $88,311 | $7,359 |
| Rivastigmine | 16 | $8,136 | $508 |
| Carbidopa-Levodopa | 97 | $4,812 | $50 |
| Memantine Hcl Er | 12 | $4,210 | $351 |
| Baclofen | 21 | $1,970 | $94 |
| Levetiracetam | 53 | $1,807 | $34 |
| Gabapentin | 71 | $1,023 | $14 |
| Donepezil | 54 | $747 | $14 |
| Diclofenac | 13 | $537 | $41 |
| Propranolol | 17 | $532 | $31 |
| Escitalopram | 19 | $403 | $21 |
| Clopidogrel | 19 | $271 | $14 |
| Clonazepam | 13 | $262 | $20 |
| Meclizine | 12 | $204 | $17 |
| Quetiapine | 17 | $184 | $11 |
| Prednisone | 13 | $136 | $10 |
| Verapamil | 13 | $87 | $7 |
| Nortriptyline | 12 | $71 | $6 |
2019: 23 drugs
| Rebif | 14 | $114,847 | $8,203 |
| Rebif Rebidose | 13 | $100,919 | $7,763 |
| Copaxone | 12 | $86,262 | $7,188 |
| Glatopa | 12 | $58,457 | $4,871 |
| Memantine Hcl Er | 11 | $6,400 | $582 |
| Rivastigmine | 13 | $6,060 | $466 |
| Rasagiline Mesylate | 13 | $5,924 | $456 |
| Carbidopa-Levodopa | 90 | $4,120 | $46 |
| Baclofen | 29 | $2,115 | $73 |
| Gabapentin | 53 | $1,457 | $27 |
| Levetiracetam | 46 | $1,442 | $31 |
| Selegiline | 11 | $1,038 | $94 |
| Donepezil | 58 | $681 | $12 |
| Clonazepam | 19 | $626 | $33 |
| Propranolol | 15 | $393 | $26 |
| Topiramate | 12 | $379 | $32 |
| Quetiapine | 24 | $334 | $14 |
| Escitalopram | 18 | $333 | $19 |
| Ranitidine | 25 | $297 | $12 |
| Clopidogrel | 21 | $227 | $11 |
| Atorvastatin | 11 | $172 | $16 |
| Prednisone | 15 | $168 | $11 |
| Verapamil | 12 | $81 | $7 |
2018: 17 drugs
| Copaxone | 23 | $169,144 | $7,354 |
| Rebif | 22 | $165,987 | $7,545 |
| Rebif Rebidose | 11 | $80,516 | $7,320 |
| Rasagiline Mesylate | 11 | $5,773 | $525 |
| Carbidopa-Levodopa | 80 | $3,903 | $49 |
| Memantine | 22 | $1,905 | $87 |
| Baclofen | 22 | $1,392 | $63 |
| Levetiracetam | 25 | $1,150 | $46 |
| Donepezil | 63 | $1,116 | $18 |
| Gabapentin | 37 | $994 | $27 |
| Quetiapine | 21 | $476 | $23 |
| Clonazepam | 12 | $402 | $34 |
| Clopidogrel | 25 | $392 | $16 |
| Topiramate | 12 | $313 | $26 |
| Escitalopram | 14 | $299 | $21 |
| Prednisone | 15 | $184 | $12 |
| Ranitidine | 14 | $153 | $11 |
2017: 21 drugs
| Copaxone | 24 | $173,542 | $7,231 |
| Rebif Rebidose | 13 | $89,343 | $6,873 |
| Namenda Xr | 25 | $20,642 | $826 |
| Rivastigmine | 24 | $10,494 | $437 |
| Carbidopa-Levodopa | 82 | $4,003 | $49 |
| Carbidopa-Levodopa-Entacapone | 12 | $3,917 | $326 |
| Memantine | 29 | $1,972 | $68 |
| Baclofen | 27 | $1,393 | $52 |
| Levetiracetam | 38 | $1,119 | $29 |
| Gabapentin | 32 | $737 | $23 |
| Donepezil | 65 | $721 | $11 |
| Clopidogrel | 25 | $428 | $17 |
| Oxcarbazepine | 12 | $412 | $34 |
| Quetiapine | 27 | $353 | $13 |
| Lidocaine | 13 | $351 | $27 |
| Escitalopram | 29 | $343 | $12 |
| Propranolol | 12 | $325 | $27 |
| Topiramate | 19 | $301 | $16 |
| Prednisone | 15 | $174 | $12 |
| Meclizine | 11 | $171 | $16 |
| Atorvastatin | 11 | $154 | $14 |
2016: 22 drugs
| Copaxone | 25 | $167,210 | $6,688 |
| Rebif Rebidose | 13 | $81,450 | $6,265 |
| Rebif | 13 | $79,591 | $6,122 |
| Namenda Xr | 37 | $29,987 | $810 |
| Rivastigmine | 46 | $19,230 | $418 |
| Exelon | 13 | $14,132 | $1,087 |
| Carbidopa-Levodopa | 83 | $3,886 | $47 |
| Memantine | 25 | $2,274 | $91 |
| Baclofen | 34 | $1,565 | $46 |
| Levetiracetam | 41 | $1,526 | $37 |
| Gabapentin | 66 | $993 | $15 |
| Donepezil | 59 | $623 | $11 |
| Clonazepam | 14 | $571 | $41 |
| Oxcarbazepine | 13 | $501 | $39 |
| Clopidogrel | 38 | $498 | $13 |
| Propranolol | 11 | $427 | $39 |
| Quetiapine | 30 | $268 | $9 |
| Topiramate | 17 | $264 | $16 |
| Escitalopram | 25 | $241 | $10 |
| Meclizine | 11 | $134 | $12 |
| Nortriptyline | 11 | $91 | $8 |
| Ranitidine | 11 | $77 | $7 |
2015: 21 drugs
| Copaxone | 24 | $148,491 | $6,187 |
| Rebif Rebidose | 13 | $73,301 | $5,639 |
| Avonex | 12 | $62,275 | $5,190 |
| Exelon | 62 | $47,639 | $768 |
| Namenda Xr | 35 | $20,813 | $595 |
| Namenda | 28 | $15,891 | $568 |
| Azilect | 13 | $6,872 | $529 |
| Carbidopa-Levodopa | 85 | $4,633 | $55 |
| Rivastigmine | 11 | $4,411 | $401 |
| Carbidopa-Levodopa-Entacapone | 12 | $3,690 | $308 |
| Memantine | 14 | $2,869 | $205 |
| Gabapentin | 79 | $2,577 | $33 |
| Baclofen | 33 | $2,401 | $73 |
| Levetiracetam | 54 | $1,591 | $29 |
| Clopidogrel | 54 | $658 | $12 |
| Donepezil | 49 | $498 | $10 |
| Oxcarbazepine | 13 | $480 | $37 |
| Quetiapine | 30 | $435 | $15 |
| Escitalopram | 23 | $240 | $10 |
| Clonazepam | 14 | $196 | $14 |
| Topiramate | 15 | $128 | $9 |
2014: 23 drugs
| Copaxone | 25 | $132,234 | $5,289 |
| Exelon | 125 | $71,271 | $570 |
| Rebif Rebidose | 13 | $67,132 | $5,164 |
| Aubagio | 11 | $53,200 | $4,836 |
| Namenda | 73 | $40,474 | $554 |
| Namenda Xr | 47 | $23,351 | $497 |
| Carbidopa-Levodopa | 81 | $4,278 | $53 |
| Levetiracetam | 86 | $3,667 | $43 |
| Gabapentin | 96 | $3,656 | $38 |
| Baclofen | 47 | $2,330 | $50 |
| Quetiapine | 37 | $1,731 | $47 |
| Voltaren | 11 | $1,480 | $135 |
| Clopidogrel | 60 | $1,238 | $21 |
| Ropinirole | 13 | $1,042 | $80 |
| Donepezil | 67 | $901 | $13 |
| Lidocaine | 23 | $767 | $33 |
| Escitalopram | 20 | $311 | $16 |
| Clonazepam | 17 | $261 | $15 |
| Promethazine | 12 | $181 | $15 |
| Prednisone | 12 | $141 | $12 |
| Levothyroxine | 12 | $134 | $11 |
| Ranitidine | 12 | $97 | $8 |
| Propranolol | 11 | $55 | $5 |
2013: 25 drugs
| Copaxone | 21 | $99,776 | $4,751 |
| Exelon | 137 | $65,054 | $475 |
| Namenda | 94 | $42,351 | $451 |
| Azilect | 11 | $8,652 | $787 |
| Clopidogrel | 63 | $5,884 | $93 |
| Carbidopa-Levodopa | 87 | $4,690 | $54 |
| Carbidopa-Levodopa-Entacapone | 12 | $4,367 | $364 |
| Levetiracetam | 68 | $4,119 | $61 |
| Donepezil | 82 | $4,068 | $50 |
| Lidoderm | 13 | $3,483 | $268 |
| Aricept | 11 | $3,476 | $316 |
| Gabapentin | 85 | $3,283 | $39 |
| Quetiapine | 38 | $3,116 | $82 |
| Lyrica | 11 | $2,777 | $252 |
| Voltaren | 19 | $2,140 | $113 |
| Ropinirole | 16 | $1,607 | $100 |
| Baclofen | 58 | $1,274 | $22 |
| Lidocaine | 16 | $965 | $60 |
| Carbidopa-Levodopa Er | 16 | $791 | $49 |
| Venlafaxine | 11 | $663 | $60 |
| Clonazepam | 25 | $439 | $18 |
| Escitalopram | 12 | $437 | $36 |
| Prednisone | 19 | $139 | $7 |
| Topiramate | 11 | $134 | $12 |
| Ranitidine | 11 | $95 | $9 |
Money from drug and device companies
$1,218 in 2025
| 2025 | 6 | 43 | None | $1,218 |
| 2024 | 8 | 33 | None | $1,182 |
| 2023 | 10 | 54 | None | $1,353 |
| 2022 | 11 | 40 | None | $1,157 |
| 2021 | 15 | 87 | None | $1,838 |
| 2020 | 7 | 23 | None | $668 |
| 2019 | 14 | 47 | None | $2,407 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| SK Life Science | None | $315 | 16 payments
|
| Catalyst Pharmaceuticals | Firdapse | $274 | 15 payments
|
| Alexion Pharmaceuticals | Ultomiris | $270 | 2 payments
|
| Eisai | Leqembi | $216 | 5 payments
|
| Lundbeck | Vyepti | $81 | 3 payments
|
| Amgen | Uplizna | $62 | 2 payments
|
See all 43 published payments
| SK Life Science | Meals · 2025-12-22 | None | $35 |
| SK Life Science | Meals · 2025-12-01 | None | $18 |
| SK Life Science | Meals · 2025-11-10 | None | $30 |
| Catalyst Pharmaceuticals | Meals · 2025-11-06 | Firdapse | $7 |
| Catalyst Pharmaceuticals | Meals · 2025-11-06 | Firdapse | $18 |
| SK Life Science | Meals · 2025-10-16 | None | $27 |
| Eisai | Meals · 2025-10-14 | Leqembi | $125 |
| Eisai | Meals · 2025-10-06 | Leqembi | $28 |
| SK Life Science | Meals · 2025-09-22 | None | $10 |
| Catalyst Pharmaceuticals | Meals · 2025-09-11 | Firdapse | $25 |
| SK Life Science | Meals · 2025-09-04 | None | $25 |
| Catalyst Pharmaceuticals | Meals · 2025-09-04 | Firdapse | $19 |
| Catalyst Pharmaceuticals | Meals · 2025-08-07 | Firdapse | $8 |
| Catalyst Pharmaceuticals | Meals · 2025-08-07 | Firdapse | $16 |
| SK Life Science | Meals · 2025-08-04 | None | $6 |
| Eisai | Meals · 2025-07-24 | Leqembi | $18 |
| SK Life Science | Meals · 2025-07-14 | None | $10 |
| Catalyst Pharmaceuticals | Meals · 2025-06-30 | Firdapse | $35 |
| Catalyst Pharmaceuticals | Meals · 2025-06-19 | Firdapse | $17 |
| Catalyst Pharmaceuticals | Meals · 2025-06-19 | Firdapse | $7 |
| Lundbeck | Meals · 2025-06-10 | Vyepti | $34 |
| SK Life Science | Meals · 2025-06-09 | None | $6 |
| Alexion Pharmaceuticals | Meals · 2025-05-29 | Ultomiris | $135 |
| Alexion Pharmaceuticals | Meals · 2025-05-29 | Ultomiris | $135 |
| Eisai | Meals · 2025-05-01 | Leqembi | $26 |
| Lundbeck | Meals · 2025-04-24 | Vyepti | $25 |
| Catalyst Pharmaceuticals | Meals · 2025-04-24 | Firdapse | $5 |
| SK Life Science | Meals · 2025-04-21 | None | $9 |
| SK Life Science | Meals · 2025-04-17 | None | $9 |
| SK Life Science | Meals · 2025-04-17 | None | $34 |
| SK Life Science | Meals · 2025-03-31 | None | $25 |
| Catalyst Pharmaceuticals | Meals · 2025-03-27 | Fycompa | $16 |
| Catalyst Pharmaceuticals | Meals · 2025-03-27 | Fycompa | $6 |
| SK Life Science | Meals · 2025-03-20 | None | $34 |
| Catalyst Pharmaceuticals | Meals · 2025-03-13 | Fycompa | $55 |
| SK Life Science | Meals · 2025-03-10 | None | $13 |
| Lundbeck | Meals · 2025-03-06 | Vyepti | $22 |
| Catalyst Pharmaceuticals | Meals · 2025-02-27 | Fycompa | $20 |
| Catalyst Pharmaceuticals | Meals · 2025-02-13 | Fycompa | $21 |
| SK Life Science | Meals · 2025-01-27 | None | $22 |
| Amgen | Meals · 2025-01-26 | Uplizna | $31 |
| Amgen | Meals · 2025-01-23 | Uplizna | $31 |
| Eisai | Meals · 2025-01-06 | Leqembi | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,182
| Catalyst Pharmaceuticals | Fycompa | $271 | 12 payments
|
| SK Life Science | Xcopri | $271 | 10 payments
|
| EMD Serono | Mavenclad | $233 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $228 | 2 payments
|
| Abbvie | Ubrelvy | $68 | 2 payments
|
| Eisai | Leqembi | $45 | 2 payments
|
| Lundbeck | Vyepti | $35 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $30 | 1 payment
|
2023: $1,353
| SK Life Science | Xcopri | $375 | 18 payments
|
| Alexion Pharmaceuticals | Ultomiris | $199 | 5 payments
|
| Harmony Biosciences | Wakix | $190 | 4 payments
|
| Catalyst Pharmaceuticals | Fycompa | $185 | 11 payments
|
| Sumitomo Pharma America | Aptiom | $160 | 8 payments
|
| Biogen | None | $100 | 1 payment
|
| Eisai | Fycompa | $63 | 3 payments
|
| Pfizer | Nurtec Odt | $32 | 1 payment
|
| Lilly USA | Amyvid | $25 | 1 payment
|
| AbbVie | Qulipta | $24 | 1 payment
|
2022: $1,157
| SK Life Science | Xcopri | $271 | 7 payments
|
| Eisai | Fycompa | $214 | 13 payments
|
| EMD Serono | Mavenclad | $195 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $137 | 2 payments
|
| Abbvie | Botox | $115 | 4 payments
|
| Allergan | Botox | $47 | 2 payments
|
| Harmony Biosciences | Wakix | $45 | 1 payment
|
| Avion Pharmaceuticals | Dhivy | $42 | 2 payments
|
| Janssen Pharmaceuticals | Ponvory | $40 | 2 payments
|
| Boston Scientific | Vercise | $26 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $25 | 1 payment
|
2021: $1,838
| Eisai | Fycompa | $420 | 42 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $243 | 10 payments
|
| Boston Scientific | Vercise | $220 | 4 payments
|
| SK Life Science | Xcopri | $200 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $165 | 7 payments
|
| Adamas Pharmaceuticals | Gocovri | $152 | 6 payments
|
| Neurocrine Biosciences | Ongentys | $125 | 1 payment
|
| AbbVie | Ubrelvy | $74 | 3 payments
|
| Amneal Pharmaceuticals | Rytary | $66 | 3 payments
|
| Ucb | Briviact | $45 | 2 payments
|
| Teva Pharmaceuticals USA | Ajovy | $36 | 1 payment
|
| Lilly USA | Emgality | $33 | 1 payment
|
| Neurelis | Valtoco | $24 | 1 payment
|
| Avion Pharmaceuticals | None | $23 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $14 | 1 payment
|
2020: $668
| Eisai | Fycompa | $323 | 15 payments
|
| Teva Pharmaceuticals USA | Ajovy | $125 | 1 payment
|
| Boston Scientific | General - Dbs | $109 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $47 | 2 payments
|
| Biogen | Avonex | $25 | 2 payments
|
| Lilly USA | Reyvow | $22 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $17 | 1 payment
|
2019: $2,407
| Eisai | Fycompa | $520 | 14 payments
|
| Novartis Pharmaceuticals | Gilenya | $314 | 4 payments
|
| Alexion Pharmaceuticals | Soliris | $306 | 5 payments
|
| Adamas Pharmaceuticals | Gocovri | $298 | 5 payments
|
| Akcea Therapeutics | Tegsedi | $282 | 3 payments
|
| Amgen | Aimovig | $252 | 5 payments
|
| Lundbeck | Northera | $125 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $122 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $77 | 4 payments
|
| US WorldMeds | Xadago | $29 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $23 | 1 payment
|
| EMD Serono | Mavenclad | $23 | 1 payment
|
| LivaNova USA | Vns Therapy | $22 | 1 payment
|
| Allergan | Botox | $13 | 1 payment
|
Professional record
- NPI
- 1851326672
- Licence
- CA A55886California A55886: Current · expires 2027-12-31
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 361 S Monroe St, San Jose, CA, 95128
- NPI first listed
- 2006-07-11
- NPI last updated
- 2008-08-12
This is when the NPI record was last certified, not a medical board exam.